Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Celyad Oncology SA is a clinical-stage biotechnology company headquartered in Mont-Saint-Guibert, Belgium, specializing in the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer treatment. The company focuses on both allogeneic and autologous CAR T candidates targeting hematological malignancies and solid tumors, leveraging proprietary technology platforms and intellectual property to address limitations in current therapies. Key product candidates include CYAD-101, an NKG2D receptor-based allogeneic CAR T using non-gene edited TIM technology for refractory metastatic colorectal cancer; CYAD-211, a short hairpin RNA-based allogeneic CAR T for relapsed or refractory multiple myeloma; and CYAD-02, an autologous NKG2D CAR T for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. With a lean team of around 18 employees, Celyad Oncology SA emphasizes strategic partnerships and innovation to advance next-generation immunotherapies, playing a role in the evolving landscape of oncology biotechnology by broadening treatment options for challenging cancer indications.
€0.24
€0.01 (-5.41%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-6400.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 88.7% YoY. Margins deteriorated 3245.7pp alongside, both lines moving the wrong way.
Negative free cash flow of -€7M. The business is consuming cash, not generating it. Operating margin contracted 3245.7pp YoY, cost discipline may be slipping.
13.6x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€21K
▼ -88.7% YoY
Net Income (TTM)
€830K
▲ +114.3% YoY
Op. Margin
-6400.00%
▼ -3245.7pp YoY
ROIC
-69.78%
▲ +35.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€7M
▼ -19.0% YoY
Op. Cash Flow (TTM)
-€2M
▲ +59.7% YoY
Net Debt
-€2M
Net Cash Position
Cash & Equiv.
€2M
Continue Research
At a P/E of 13.6, Celyad Oncology SA (CYAD.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Celyad Oncology SA scores 19/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Celyad Oncology SA scores 19 out of 100 on Intrinsiqq's quality score, passing 2 of 5 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -6,400.0% operating margin and a -69.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CYAD.XBRU's valuation and scores 19/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.